Anne-Claire Fougerousse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne-Claire Fougerousse has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
François Maccari
Department of Dermatology Hôpital d'Instruction des Armées Begin Saint Mandé France
8 shared publicationsZiad Reguiai
Department of Dermatology Polyclinique Courlancy Reims‐Bezannes France
8 shared publicationsF. Maccari
Cabinet Médical La Varenne Saint Hilaire France
7 shared publications- Charles Taieb
Patients Priority EMMA Fontenay‐sous‐Bois France
5 shared publications - Emmanuel Mahe
Department of Dermatology Hôpital Victor Dupouy Argenteuil France
5 shared publications J. Parier
Dermatology, Private Practitioner, Saint-Maur-des-Fossés, France
5 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-6
Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report
Prurigo nodularis (PN) is a chronic inflammatory dermatosis characterized by intensely pruritic hyperkeratotic nodules affecting the trunk and extremities. Despite an expanding therapeutic armamentarium including dupilumab and nemolizumab, a subset of patients remains inadequately controlled. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used in the management of type 2 diabetes and obesity, have provided emerging evidence supporting immunomodulatory and anti-inflammatory effects in several chronic inflammatory dermatoses. We report the case of a 64-year-old man with severe, treatment-refractory PN who had failed multiple lines of therapy over four years, including potent topical corticosteroids, dupilumab, and methotrexate. Following initiation of semaglutide for obesity, and with no change to his background PN treatment, a dramatic and progressive clinical improvement was observed. To our knowledge, this is the first reported case of PN improvement under GLP-1 RA therapy. The potential mechanisms underlying this benefit include modulation of low-grade chronic inflammation, direct effects on GLP-1 receptor-expressing immune cells, possible modulation of Th2 immune response, and anti-nociceptive action on pruritus via central and peripheral neuro-immune pathways. This observation highlights the potential of GLP-1 RAs as adjunctive therapy in refractory inflammatory dermatoses and warrants further investigation.
- 1 August 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-6
Open AccessDramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report
Prurigo nodularis (PN) is a chronic inflammatory dermatosis characterized by intensely pruritic hyperkeratotic nodules affecting the trunk and extremities. Despite an expanding therapeutic armamentarium including dupilumab and nemolizumab, a subset of patients remains inadequately controlled. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used in the management of type 2 diabetes and obesity, have provided emerging evidence supporting immunomodulatory and anti-inflammatory effects in several chronic inflammatory dermatoses. We report the case of a 64-year-old man with severe, treatment-refractory PN who had failed multiple lines of therapy over four years, including potent topical corticosteroids, dupilumab, and methotrexate. Following initiation of semaglutide for obesity, and with no change to his background PN treatment, a dramatic and progressive clinical improvement was observed. To our knowledge, this is the first reported case of PN improvement under GLP-1 RA therapy. The potential mechanisms underlying this benefit include modulation of low-grade chronic inflammation, direct effects on GLP-1 receptor-expressing immune cells, possible modulation of Th2 immune response, and anti-nociceptive action on pruritus via central and peripheral neuro-immune pathways. This observation highlights the potential of GLP-1 RAs as adjunctive therapy in refractory inflammatory dermatoses and warrants further investigation.
- 18 March 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (2) , 103477
Hidradenitis suppurativa in transgender patients: A case series
- 18 March 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (2) , 103477
Hidradenitis suppurativa in transgender patients: A case series
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Improved Quality of Life and Sleep in Psoriasis Patients Treated With Guselkumab: The CASSIOPEE Study
Background: Psoriasis has physical, psychological, and social consequences that extend beyond visible lesions. Quality of life (QoL) is frequently affected by fatigue, sleep disturbance, and impaired intimacy or social functioning. Although biologics can achieve durable skin clearance, their broader effects on daily well‐being in routine practice are less well documented. The CASSIOPEE study assessed these multidimensional outcomes in patients treated with guselkumab. Objectives: To evaluate the impact of guselkumab on QoL and objectively measured sleep in adults with moderate‐to‐severe psoriasis treated in routine clinical practice. Methods: CASSIOPEE was a prospective, noninterventional, multicentre French study. Adults with moderate‐to‐severe psoriasis initiating guselkumab were followed for 6 months. The primary endpoint was Dermatology Life Quality Index (DLQI) response at month 6 (M6). Secondary outcomes included patient‐reported measures of general health (EQ‐5D‐5L), fatigue (FACIT‐Fatigue), anhedonia (SHAPS), sexual QoL (RSS), cognitive function (PDQ‐5), alexithymia (TAS‐20), and monthly electronic ratings of pain and pruritus. Sleep and physical activity were continuously monitored using a wearable device. Results: Among the 207 enrolled patients, 88.9% achieved the DLQI minimal clinically important difference (MCID) by M6 and 60.1% had a DLQI score of 0/1. Sleep duration and quality improved, with 74.5% of patients gaining > 15 min/night and the proportion with high sleep quality increasing from 4.2% to 23.8%. Patient‐reported outcomes showed marked reductions in pruritus, skin pain, and fatigue, together with improvements in general health, sexual QoL, cognitive function, and anhedonia. Clinical effectiveness was reflected by 88.1% of patients achieving a Physician’s Global Assessment (PGA) score ≤ 1 and 55.1% reaching complete skin clearance at M6. Guselkumab was well tolerated; most adverse events were mild and 1.8% led to treatment discontinuation. Conclusions: In routine practice, guselkumab was associated with broad benefits across skin and QoL domains, including a marked improvement in wearable‐confirmed sleep outcomes that paraleled symptom relief.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessImproved Quality of Life and Sleep in Psoriasis Patients Treated With Guselkumab: The CASSIOPEE Study
Background: Psoriasis has physical, psychological, and social consequences that extend beyond visible lesions. Quality of life (QoL) is frequently affected by fatigue, sleep disturbance, and impaired intimacy or social functioning. Although biologics can achieve durable skin clearance, their broader effects on daily well‐being in routine practice are less well documented. The CASSIOPEE study assessed these multidimensional outcomes in patients treated with guselkumab. Objectives: To evaluate the impact of guselkumab on QoL and objectively measured sleep in adults with moderate‐to‐severe psoriasis treated in routine clinical practice. Methods: CASSIOPEE was a prospective, noninterventional, multicentre French study. Adults with moderate‐to‐severe psoriasis initiating guselkumab were followed for 6 months. The primary endpoint was Dermatology Life Quality Index (DLQI) response at month 6 (M6). Secondary outcomes included patient‐reported measures of general health (EQ‐5D‐5L), fatigue (FACIT‐Fatigue), anhedonia (SHAPS), sexual QoL (RSS), cognitive function (PDQ‐5), alexithymia (TAS‐20), and monthly electronic ratings of pain and pruritus. Sleep and physical activity were continuously monitored using a wearable device. Results: Among the 207 enrolled patients, 88.9% achieved the DLQI minimal clinically important difference (MCID) by M6 and 60.1% had a DLQI score of 0/1. Sleep duration and quality improved, with 74.5% of patients gaining > 15 min/night and the proportion with high sleep quality increasing from 4.2% to 23.8%. Patient‐reported outcomes showed marked reductions in pruritus, skin pain, and fatigue, together with improvements in general health, sexual QoL, cognitive function, and anhedonia. Clinical effectiveness was reflected by 88.1% of patients achieving a Physician’s Global Assessment (PGA) score ≤ 1 and 55.1% reaching complete skin clearance at M6. Guselkumab was well tolerated; most adverse events were mild and 1.8% led to treatment discontinuation. Conclusions: In routine practice, guselkumab was associated with broad benefits across skin and QoL domains, including a marked improvement in wearable‐confirmed sleep outcomes that paraleled symptom relief.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Abrocitinib: 1‐Year Real‐Life Experience From the French OMCCI Registry
Abrocitinib is a selective inhibitor of Janus kinase 1 approved to treat moderate‐to‐severe atopic dermatitis (AD). Phase 3 clinical trials have demonstrated the efficacy and safety of abrocitinib; nevertheless, there is a need for real‐world patient data. This study aimed to assess the efficacy and safety of abrocitinib in patients with AD in the real‐world setting. In this prospective, observational, multicentre study, all patients with AD enrolled in the French registry Observatory of Chronic Inflammatory Skin Diseases (‘Observatoire Maladies Cutanées Chroniques Inflammatoires’; OMCCI) who received abrocitinib were included. Effectiveness was evaluated using outcome measures provided by clinicians and patients, including quality‐of‐life scores. Adverse events (AEs) were also assessed. Sixty‐five patients were included, 45 with 1 year of follow‐up. Abrocitinib treatment resulted in a significant decrease in disease severity at 12 months. After 1 year, median (interquartile range; IQR) Eczema Area and Severity Index Score decreased from 16.00 (9.10, 19.00) to 2.10 (0.80, 6.40), median (IQR) Dermatology Life Quality Index improved from 10.00 (6.00, 13.00) to 1.00 (0.00, 7.00), median (IQR) Mental Component Score and Physical Component Score increased from 48.14 (44.60, 56.82) to 57.21 (48.97, 60.12) and from 30.84 (28.13, 34.93) to 34.85 (30.74, 39.39), respectively, indicating improvement; all changes from baseline were significant ( p < 0.001). The most frequently reported AEs included 13 (23.2%) cases of acne and 11 (19.6%) cases of gastrointestinal symptoms. Eleven patients discontinued abrocitinib treatment due to ineffectiveness (8 [17.8%]) or AEs (3 [6.7%]). Abrocitinib can be an effective and safe treatment for patients with moderate‐to‐severe AD in daily clinical practice.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessAbrocitinib: 1‐Year Real‐Life Experience From the French OMCCI Registry
Abrocitinib is a selective inhibitor of Janus kinase 1 approved to treat moderate‐to‐severe atopic dermatitis (AD). Phase 3 clinical trials have demonstrated the efficacy and safety of abrocitinib; nevertheless, there is a need for real‐world patient data. This study aimed to assess the efficacy and safety of abrocitinib in patients with AD in the real‐world setting. In this prospective, observational, multicentre study, all patients with AD enrolled in the French registry Observatory of Chronic Inflammatory Skin Diseases (‘Observatoire Maladies Cutanées Chroniques Inflammatoires’; OMCCI) who received abrocitinib were included. Effectiveness was evaluated using outcome measures provided by clinicians and patients, including quality‐of‐life scores. Adverse events (AEs) were also assessed. Sixty‐five patients were included, 45 with 1 year of follow‐up. Abrocitinib treatment resulted in a significant decrease in disease severity at 12 months. After 1 year, median (interquartile range; IQR) Eczema Area and Severity Index Score decreased from 16.00 (9.10, 19.00) to 2.10 (0.80, 6.40), median (IQR) Dermatology Life Quality Index improved from 10.00 (6.00, 13.00) to 1.00 (0.00, 7.00), median (IQR) Mental Component Score and Physical Component Score increased from 48.14 (44.60, 56.82) to 57.21 (48.97, 60.12) and from 30.84 (28.13, 34.93) to 34.85 (30.74, 39.39), respectively, indicating improvement; all changes from baseline were significant ( p < 0.001). The most frequently reported AEs included 13 (23.2%) cases of acne and 11 (19.6%) cases of gastrointestinal symptoms. Eleven patients discontinued abrocitinib treatment due to ineffectiveness (8 [17.8%]) or AEs (3 [6.7%]). Abrocitinib can be an effective and safe treatment for patients with moderate‐to‐severe AD in daily clinical practice.
- 10 July 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (2)
Withdrawal of biologic agents before pregnancy is associated with psoriasis flare
- 10 July 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (2)
Withdrawal of biologic agents before pregnancy is associated with psoriasis flare
- Open Access
- 19 March 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (4) , 732-740
Patient's Perspective on the Impact of Psoriasis on Their Quality of Life After 1 Year of Tildrakizumab Treatment: Despite Clinical Improvement, Persistence of a Potential Mental Cicatricial Memory of the Disease
Background: Tildrakizumab showed high efficacy and safety for treating moderate‐to‐severe psoriasis in clinical trials. The development of biologics to treat psoriasis has allowed us to aim for increasingly ambitious objectives. However, patients' and physicians' perspectives on therapeutic goals and satisfaction concerning treatments may sometimes differ.Objectives: To analyze the efficacy and safety of tildrakizumab and the impact of the psoriasis improvement regarding the physicians' and patients' point of view, in daily practice, after 1 year of treatment.Methods: A prospective multicentric study was conducted in patients who were initiated with tildrakizumab for moderate‐to‐severe psoriasis. Assessments of psoriasis and its impact on patients' lives were performed at tildrakizumab initiation and after 6 and 12 months of treatment.Results: At baseline, psoriasis deeply affected patients' lives, with 42% showing signs of clinical depression and 34.6% experiencing genital involvement with significant impact on their sex life. After 1 year, tildrakizumab was, overall, effective and safe, even in difficult‐to‐treat areas. Psoriasis Area Severity Index score decreased from 13.6 to 2.3, SF12‐mental component score improved from 41 to 48.7 and Dermatology Life Quality Index dropped from 10.4 to 2.5. Despite these improvements, some patients remained dissatisfied, expressing concerns about relapse and persistence of mental impact of the disease over the long term.Conclusions: Tildrakizumab confirmed its efficacy and safety for the treatment of moderate‐to‐severe psoriasis. However, despite good control of their disease, some patients remained dissatisfied, over the long time, raising the issue of the cumulative mental impact of a disease left with no effective treatment for too long before the initiation of an effective treatment. These findings suggest that early treatment of psoriasis with effective therapies is important not only to target tissue‐resident memory T cells, as indicated by recent studies, but also to potentially address patients' cicatricial memory of their disease.
- 19 March 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (4) , 732-740
Open AccessPatient's Perspective on the Impact of Psoriasis on Their Quality of Life After 1 Year of Tildrakizumab Treatment: Despite Clinical Improvement, Persistence of a Potential Mental Cicatricial Memory of the Disease
Background: Tildrakizumab showed high efficacy and safety for treating moderate‐to‐severe psoriasis in clinical trials. The development of biologics to treat psoriasis has allowed us to aim for increasingly ambitious objectives. However, patients' and physicians' perspectives on therapeutic goals and satisfaction concerning treatments may sometimes differ.Objectives: To analyze the efficacy and safety of tildrakizumab and the impact of the psoriasis improvement regarding the physicians' and patients' point of view, in daily practice, after 1 year of treatment.Methods: A prospective multicentric study was conducted in patients who were initiated with tildrakizumab for moderate‐to‐severe psoriasis. Assessments of psoriasis and its impact on patients' lives were performed at tildrakizumab initiation and after 6 and 12 months of treatment.Results: At baseline, psoriasis deeply affected patients' lives, with 42% showing signs of clinical depression and 34.6% experiencing genital involvement with significant impact on their sex life. After 1 year, tildrakizumab was, overall, effective and safe, even in difficult‐to‐treat areas. Psoriasis Area Severity Index score decreased from 13.6 to 2.3, SF12‐mental component score improved from 41 to 48.7 and Dermatology Life Quality Index dropped from 10.4 to 2.5. Despite these improvements, some patients remained dissatisfied, expressing concerns about relapse and persistence of mental impact of the disease over the long term.Conclusions: Tildrakizumab confirmed its efficacy and safety for the treatment of moderate‐to‐severe psoriasis. However, despite good control of their disease, some patients remained dissatisfied, over the long time, raising the issue of the cumulative mental impact of a disease left with no effective treatment for too long before the initiation of an effective treatment. These findings suggest that early treatment of psoriasis with effective therapies is important not only to target tissue‐resident memory T cells, as indicated by recent studies, but also to potentially address patients' cicatricial memory of their disease.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 2459-2464
AI in Hidradenitis Suppurativa: Expert Evaluation of Patient-Facing Information
Purpose: This study investigates the accuracy of Artificial Intelligence (AI) chatbots, ChatGPT and Bard, in providing information on Hidradenitis Suppurativa (HS), aiming to explore their potential in assisting HS patients by offering insights into symptoms, thus possibly reducing the diagnostic and treatment time gap. Patients and Methods: Using questions formulated with the help of HS patient associations, both ChatGPT and Bard were assessed. Responses to these questions were evaluated by 18 hS experts. Results: ChatGPT’s responses were considered accurate in 86% of cases, significantly outperforming Bard, which only achieved 14% accuracy. Despite the general efficacy of ChatGPT in providing relevant information across a range of HS-related queries, both AI systems showed limitations in offering adequate advice on treatments. The study identifies a significant difference in the performance of the two AIs, emphasizing the need for improvement in AI-driven medical advice, particularly regarding treatment options. Conclusion: The study highlights the potential of AI chatbots, particularly ChatGPT, in supporting HS patients by improving symptom understanding and potentially reducing the time to diagnosis and treatment. AI chatbots, while promising, cannot yet substitute for professional medical diagnosis and treatment, indicating the importance of enhancing AI capabilities for more accurate and reliable medical information dissemination.
- 1 November 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 2459-2464
Open AccessAI in Hidradenitis Suppurativa: Expert Evaluation of Patient-Facing Information
Purpose: This study investigates the accuracy of Artificial Intelligence (AI) chatbots, ChatGPT and Bard, in providing information on Hidradenitis Suppurativa (HS), aiming to explore their potential in assisting HS patients by offering insights into symptoms, thus possibly reducing the diagnostic and treatment time gap. Patients and Methods: Using questions formulated with the help of HS patient associations, both ChatGPT and Bard were assessed. Responses to these questions were evaluated by 18 hS experts. Results: ChatGPT’s responses were considered accurate in 86% of cases, significantly outperforming Bard, which only achieved 14% accuracy. Despite the general efficacy of ChatGPT in providing relevant information across a range of HS-related queries, both AI systems showed limitations in offering adequate advice on treatments. The study identifies a significant difference in the performance of the two AIs, emphasizing the need for improvement in AI-driven medical advice, particularly regarding treatment options. Conclusion: The study highlights the potential of AI chatbots, particularly ChatGPT, in supporting HS patients by improving symptom understanding and potentially reducing the time to diagnosis and treatment. AI chatbots, while promising, cannot yet substitute for professional medical diagnosis and treatment, indicating the importance of enhancing AI capabilities for more accurate and reliable medical information dissemination.
- Open Access
- 21 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5598
Factors Affecting Wound Healing after the Wide Surgical Excision of Hidradenitis Suppurativa Lesions
Background: Hidradenitis suppurativa (HS) is a chronic and inflammatory disease. Its management depends on the stage and extent of the disease. Surgery plays an important role in treatment options. This study explores the factors influencing healing after wide excision. Methods: This study analyzed data from patients who underwent wide excision for HS between 2016 and 2021. Results: A total of 160 patients (64.4% women) were included, with surgeries performed in the axillae (70), inguinal-ano-genital (73), and other locations (17, including gluteal). The mean TTWC was 74 ± 6 days, varying from 11 to 445 days. Factors negatively influencing TTWC included axillary localization (p < 0.001) and the presence of another inflammatory disease (p = 0.017). Factors positively influencing healing were smoking (p = 0.011). Obesity or being overweight did not impact the TTWC in multivariate analysis, although overweight was significant in univariate analysis. Conclusions: While smoking cessation remains important in the management of HS, it does not appear to be a prerequisite for successful surgical treatment. Conversely, patients with an inflammatory disease or those undergoing surgery for an axillary lesion exhibit slower healing and should be informed of potential healing delays before surgery.
- 21 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5598
Open AccessFactors Affecting Wound Healing after the Wide Surgical Excision of Hidradenitis Suppurativa Lesions
Background: Hidradenitis suppurativa (HS) is a chronic and inflammatory disease. Its management depends on the stage and extent of the disease. Surgery plays an important role in treatment options. This study explores the factors influencing healing after wide excision. Methods: This study analyzed data from patients who underwent wide excision for HS between 2016 and 2021. Results: A total of 160 patients (64.4% women) were included, with surgeries performed in the axillae (70), inguinal-ano-genital (73), and other locations (17, including gluteal). The mean TTWC was 74 ± 6 days, varying from 11 to 445 days. Factors negatively influencing TTWC included axillary localization (p < 0.001) and the presence of another inflammatory disease (p = 0.017). Factors positively influencing healing were smoking (p = 0.011). Obesity or being overweight did not impact the TTWC in multivariate analysis, although overweight was significant in univariate analysis. Conclusions: While smoking cessation remains important in the management of HS, it does not appear to be a prerequisite for successful surgical treatment. Conversely, patients with an inflammatory disease or those undergoing surgery for an axillary lesion exhibit slower healing and should be informed of potential healing delays before surgery.
- 17 July 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , 2149-2155
Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)
Background: Clinical trials and real‐life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation.Objectives: (1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors.Methods: This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3–6 months after inclusion) and at visit 3 (corresponding to the last medical visit).Results: After multivariate analysis, the only factors associated with a complete resolution of dupilumab‐associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47–55) (p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82–62.63) (p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94–99.66) (p = 0.002).Conclusions: Although uncommon, severe dupilumab‐associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered.
- 17 July 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , 2149-2155
Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)
Background: Clinical trials and real‐life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation.Objectives: (1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors.Methods: This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3–6 months after inclusion) and at visit 3 (corresponding to the last medical visit).Results: After multivariate analysis, the only factors associated with a complete resolution of dupilumab‐associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47–55) (p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82–62.63) (p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94–99.66) (p = 0.002).Conclusions: Although uncommon, severe dupilumab‐associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered.
- 16 July 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (10) , 2205-2212
Tocilizumab-induced psoriatic eruption : a case report and a case-based review
Background: Cases of psoriasis associated with Tocilizumab (TCZ) are scarce. Objective: To describe a new case of TCZ-associated psoriasis and to perform a case-based review of similar cases. Methods: We searched Medline/Pubmed, Embase, Scopus, Web of Science, and Directory of Open Access Journals databases using the terms « Tocilizumab » and « Psoriasis » in the French and English literature. Results: We report a 70-year-old woman with a history of Rheumatoid Arthritis who developed Infliximab-induced plaque psoriatic eruption of the soles and palms, that resolved after Infliximab interruption, then relapsed after TCZ relay, and eventually resolved after TCZ interruption. Including our case, we identified 16 cases of TCZ-induced psoriatic eruption. Three (21%) out of 14 patients had a history of cutaneous psoriasis – data were not available for 2 patients. Eight (50%) patients had previously received TNFα antagonists. TCZ was stopped for 10 patients and continued for 4 patients. For the 2 remaining patients, the interval between two injections of TCZ was shortened. All the patients with available follow-up data had an improvement of the eruption within 4 weeks. Conclusion: To conclude, in case of TCZ-induced psoriatic eruption and in light of the published cases, we suggest using topical steroids and reassessing the patient 4 weeks later. If no healing is obtained, we suggest stopping TCZ, and treating the underlying disease with another drug. When no other drug is available, while waiting for more data regarding the value of IL-6 levels, it can be discussed to increase TCZ regimen, as it has been successful for 2 authors. Efficacy assessment of the chosen attitude should not take place before 4 weeks.
- 16 July 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (10) , 2205-2212
Tocilizumab-induced psoriatic eruption : a case report and a case-based review
Background: Cases of psoriasis associated with Tocilizumab (TCZ) are scarce. Objective: To describe a new case of TCZ-associated psoriasis and to perform a case-based review of similar cases. Methods: We searched Medline/Pubmed, Embase, Scopus, Web of Science, and Directory of Open Access Journals databases using the terms « Tocilizumab » and « Psoriasis » in the French and English literature. Results: We report a 70-year-old woman with a history of Rheumatoid Arthritis who developed Infliximab-induced plaque psoriatic eruption of the soles and palms, that resolved after Infliximab interruption, then relapsed after TCZ relay, and eventually resolved after TCZ interruption. Including our case, we identified 16 cases of TCZ-induced psoriatic eruption. Three (21%) out of 14 patients had a history of cutaneous psoriasis – data were not available for 2 patients. Eight (50%) patients had previously received TNFα antagonists. TCZ was stopped for 10 patients and continued for 4 patients. For the 2 remaining patients, the interval between two injections of TCZ was shortened. All the patients with available follow-up data had an improvement of the eruption within 4 weeks. Conclusion: To conclude, in case of TCZ-induced psoriatic eruption and in light of the published cases, we suggest using topical steroids and reassessing the patient 4 weeks later. If no healing is obtained, we suggest stopping TCZ, and treating the underlying disease with another drug. When no other drug is available, while waiting for more data regarding the value of IL-6 levels, it can be discussed to increase TCZ regimen, as it has been successful for 2 authors. Efficacy assessment of the chosen attitude should not take place before 4 weeks.